Bioma Genetics operates in a segment still largely untapped by healthtechs, offering genomic and microbiota testing applied across multiple medical specialties. Founded by Rafael Malagoli, a biomedical scientist and experienced entrepreneur who had previously founded and sold a company in the sector to Grupo Dasa, Bioma combines scientific expertise with business vision.

Our engagement with the Bioma Genetics team aimed to structure a significant fundraising process, attracting a strategic investor capable of strengthening corporate governance and positioning the company on the path toward Venture Capital.

Preparation for the transaction included developing an equity story that connected Bioma's market potential with the founding team's execution capabilities. This storytelling was crucial when approaching investors. Pre-roadshow organization, information structuring, and the team’s resilience throughout the process were decisive in attracting major players such as Angra Partners—one of Brazil’s most traditional funds—and Polaris Investimentos, with extensive experience in the sector.

Bioma's entry into the Venture Capital ecosystem marks a milestone in its journey, which began in 2017. With the funds raised, the company will increase its investments in R&D to launch innovative new products, further consolidating its market presence and advancing toward its goal of becoming one of the leaders in its segment.